Pharmaceuticals

Biosimilar Interleukins Market Growth Opportunities Across 2026–2030

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Biosimilar Interleukins Market From 2026 To 2030?

The biosimilar interleukins market has seen substantial growth in recent years. It is anticipated to expand from $7.52 billion in 2025 to $10.54 billion in 2026, with a compound annual growth rate (CAGR) of 40.2%. This past expansion can be ascribed to the elevated cost of originator interleukin biologics, the increasing prevalence of autoimmune and inflammatory diseases, the escalating burden of rheumatoid arthritis and psoriasis, limited patient access to biologic therapies, and a growing recognition of biologics in immune modulation.

The biosimilar interleukins market size is projected to experience substantial expansion in the coming years. This market is expected to grow to $41.22 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 40.6%. The anticipated growth during the forecast period is driven by factors such as the expiration of patents for branded interleukins, the enlargement of biosimilar clinical pipelines, increasing acceptance of biosimilars among physicians, supportive government policies promoting biosimilar usage, and a rising demand for affordable biologic treatments for cancer and immunology. Prominent trends throughout the forecast period include the increasing adoption of biosimilar interleukins in treating autoimmune diseases, a growing demand for cost-effective alternatives to originator biologics, the expansion of biosimilar approvals across multiple indications, wider use of interleukins in chronic inflammatory disorders, and the reinforcement of regulatory frameworks that support biosimilar adoption.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

What Key Drivers Are Influencing The Growth Of The Biosimilar Interleukins Market?

The increasing occurrence of autoimmune conditions like psoriasis and rheumatoid arthritis is anticipated to stimulate the growth of the interleukin biosimilars market during the forecast period. Autoimmune disorders are characterized by immune cells failing to distinguish healthy cells from potentially harmful antibodies. Biologic medications, such as anti-interleukin antibodies, have demonstrated significant clinical benefits in regulating and directing cell proliferation, activation, and migration. For example, reports published by the National Institutes of Health (NIH) in February 2024 indicated estimated annual global increases of 19.1% in the incidence and 12.5% in the prevalence of autoimmune diseases. Consequently, the rising prevalence of these conditions is boosting the demand for the biosimilar interleukins market and is expected to drive its expansion.

Which Segments Are Included In The Analysis Of The Biosimilar Interleukins Market?

The biosimilar interleukins market covered in this report is segmented –

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6

2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Subsegments:

1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management

2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment

3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders

4) By IL-5: Asthma Treatment, Eosinophilic Disorders

5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment

Which Trends Are Impacting The Growth Of The Biosimilar Interleukins Market?

Leading companies in the biosimilar interleukins market are introducing novel products, such as Tofidence (tocilizumab-bavi), to enhance their market profitability. Tofidence functions as a monoclonal antibody that specifically targets and binds to interleukin-6 receptors, and it is utilized in the management of various inflammatory autoimmune disorders. For instance, in September 2023, Biogen Inc., a US-based biotechnology company, obtained FDA approval for Tofidence (tocilizumab-bavi), establishing it as the first biosimilar to reference Genentech’s Actemra (tocilizumab). Tofidence is administered through intravenous infusion and has received authorization for the treatment of severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Which Key Industry Participants Are Active In The Biosimilar Interleukins Market?

Major companies operating in the biosimilar interleukins market are Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.

Read the full biosimilar interleukins market report here:

https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Biosimilar Interleukins Market?

North America was the largest region in the biosimilar interleukins market in 2025. The regions covered in the biosimilar interleukins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biosimilar Interleukins Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3433&type=smp

Browse Through More Reports Similar to the Global Biosimilar Interleukins Market 2026, By The Business Research Company

Generic Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795